Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236067 · ClinicalTrials.gov registry record · Phase 3
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
A Phase 3 study of Generalized Anxiety Disorder, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
- 20
- Study locations
NCT00236067: Completed Phase 3 study of Generalized Anxiety Disorder, sponsored by Cephalon.
NCT00236067 is a Phase 3 study of Generalized Anxiety Disorder that has completed, run by Cephalon. The registered enrollment target is 440 participants, above the 206-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (114% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00236067, a Phase 3 study of Generalized Anxiety Disorder, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
Conditions Studied
Interventions
- DRUG Gabitril
Study Locations (20)
New York
- Social Psychiatry Research Inst. - Brooklyn
- Neurobehavioral Research, Inc. - Lawrence
- Social Psychiatry Research Inst. - New York
- The Medical Research Network - New York
California
- Southwestern Research Institute - Beverly Hills
- Pharmacology Research Institute - Northridge
- Pacific Clinical Research - Orange
Alabama
- Birmingham Research Group - Birmingham
Georgia
- Carman Research - Smyrna
Hawaii
- Hawaii Clinical Research Center - Honolulu
Kentucky
- Hartford Research Group - Florence
Michigan
- Summit Research Network - Okemos
New Jersey
- CNS Research Institute - Clementon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
What the finished NCT00236067 record still lists
NCT00236067 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, above the 206-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (114% higher).
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 1 intervention - of which Gabitril is the first listed.
NCT00236067 names 20 study sites across 15 states, led by New York, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00236067 about?
NCT00236067 is a clinical study titled "A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder". The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
What is the current status of trial NCT00236067?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2004-10. Estimated completion is 2006-03.
What conditions does trial NCT00236067 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT00236067?
The interventions under investigation include: Gabitril (DRUG).
Who is sponsoring clinical trial NCT00236067?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00236067 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Hawaii, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00236067's enrollment target sits among peer trials
440 6th of 48 higher than 43 of 48 other Generalized Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
RECRUITING · Phase 3
-
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
RECRUITING · Phase 3
-
Long Term Chamomile Therapy for Anxiety
COMPLETED · Phase 3
-
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia